Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir vs Valganciclovir for CMV Prophylaxis in Kidney Transplant Recipients
NCT07571135Phase 4Not yet recruiting
- Start
- May 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms). Primary endpoint: Incidence of clinically significant CMV infection at 12 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07571135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571135.